KEYTRUDA SC DIN 02565382
Status: Marketed
Holder: MERCK CANADA INC
Health Canada record
| Active ingredient(s) | PEMBROLIZUMAB 165 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L01FF02 PEMBROLIZUMAB |
|---|
| Original market date | 05-Mar-2026 |
|---|
| Current status date | 05-Mar-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Merck Canada Inc — licence 101380, currently licensed, last inspection rating C (2023-07-17).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing PEMBROLIZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02456869 | KEYTRUDA | MERCK CANADA INC | Solution | PEMBROLIZUMAB 25 MG | Marketed |
| 02441152 | KEYTRUDA | MERCK CANADA INC | Powder For Solution | PEMBROLIZUMAB 50 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 36821 | 2026-02-03 | Supplement to a New Drug Submission (SNDS) | New dosage form. Additional manufacturing sites. |
Request a quote for KEYTRUDA SC
How to read a Canadian DIN record